Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Continuous Manufacturing Mean Continuous Generic Delay? FDA Hears AAM's Warning

Executive Summary

Association for Accessible Medicines calls for US FDA to guard against use of continuous manufacturing methods to protect brand drugs from batch-manufactured generic drugs that may be of lower but still acceptable quality. Then FDA approves first generic of a continuously manufactured drug.

Advertisement

Related Content

AAM, PhRMA Renew Rivalry In Hatch-Waxman Public Comments
FDA Clarifies Scope Of Its Emerging Technology Program
Brand 'Evergreening' Piques FDA Interest, But Solutions Remain Elusive
Continuous Manufacturing Poised to Disrupt Pharma Sector
FDA Talks Up Continuous Manufacturing, Offers Assistance
J&J To Launch Prezista For HIV Immediately Following FDA Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122069

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel